Voxilaprevir

Summary

Voxilaprevir (CHEMBL3707372) is an approved small molecule; indicated across 2 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 8
• Chemistry: 861 Da · C42H58F2N6O9S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707372
Name	Voxilaprevir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	122197547
Molecular formula	C42H58F2N6O9S
Molecular weight	861
InChIKey	MKDALIOACIEUJM-XCFCBFDASA-N

SMILES: CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(C)C)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C

IUPAC name: (1R,18R,20R,24S,27S,28S)-24-tert-butyl-28-ethyl-13,13-difluoro-7-methoxy-N-[(1R,2S)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]-2-propan-2-ylcyclopropyl]-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide

Also known as: GS-9857, Voxilaprevir, Voxilaprevir component of vosevi, VOXILAPREVIR

Patent coverage: 200 distinct patent families (520 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220
hepatitis C virus infection	1	MONDO:0005231	EFO:0003047

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	4
PHASE1	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03619837	PHASE4	COMPLETED	Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
NCT03888729	PHASE4	UNKNOWN	Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
NCT05467826	PHASE4	UNKNOWN	Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
NCT05717400	PHASE4	TERMINATED	Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NCT02745535	PHASE2	COMPLETED	Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
NCT02185794	PHASE1	COMPLETED	Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
NCT02397707	PHASE1	COMPLETED	Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
NCT02402452	PHASE1	COMPLETED	Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).